165 related articles for article (PubMed ID: 18378392)
1. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.
Dings RP; Van Laar ES; Webber J; Zhang Y; Griffin RJ; Waters SJ; MacDonald JR; Mayo KH
Cancer Lett; 2008 Jul; 265(2):270-80. PubMed ID: 18378392
[TBL] [Abstract][Full Text] [Related]
2. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Woo MH; Peterson JK; Billups C; Liang H; Bjornsti MA; Houghton PJ
Cancer Chemother Pharmacol; 2005 May; 55(5):411-9. PubMed ID: 15503024
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
6. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
7. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells.
Dings RP; Williams BW; Song CW; Griffioen AW; Mayo KH; Griffin RJ
Int J Cancer; 2005 Jun; 115(2):312-9. PubMed ID: 15688384
[TBL] [Abstract][Full Text] [Related]
8. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin.
Dings RP; Yokoyama Y; Ramakrishnan S; Griffioen AW; Mayo KH
Cancer Res; 2003 Jan; 63(2):382-5. PubMed ID: 12543791
[TBL] [Abstract][Full Text] [Related]
9. Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Invest New Drugs; 2008 Oct; 26(5):407-15. PubMed ID: 18227973
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
11. Recombinant adeno-associated virus-delivered anginex inhibits angiogenesis and growth of HUVECs by regulating the Akt, JNK and NF-κB signaling pathways.
Ma K; Wang C; Geng Q; Fan Y; Ning J; Yang H; Dong X; Dong D; Guo Y; Wei X; Li E; Wu Y
Oncol Rep; 2016 Jun; 35(6):3505-13. PubMed ID: 27035232
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene.
Dings RP; Van Laar ES; Loren M; Webber J; Zhang Y; Waters SJ; Macdonald JR; Mayo KH
Bioconjug Chem; 2010 Jan; 21(1):20-7. PubMed ID: 20020769
[TBL] [Abstract][Full Text] [Related]
13. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
14. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models.
van der Schaft DW; Dings RP; de Lussanet QG; van Eijk LI; Nap AW; Beets-Tan RG; Bouma-Ter Steege JC; Wagstaff J; Mayo KH; Griffioen AW
FASEB J; 2002 Dec; 16(14):1991-3. PubMed ID: 12397082
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenesis and anti-tumor activity of recombinant anginex.
Brandwijk RJ; Dings RP; van der Linden E; Mayo KH; Thijssen VL; Griffioen AW
Biochem Biophys Res Commun; 2006 Oct; 349(3):1073-8. PubMed ID: 16970922
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Estes L
Cancer Chemother Pharmacol; 2002 May; 49(5):412-8. PubMed ID: 11976836
[TBL] [Abstract][Full Text] [Related]
17. [Experimental therapy with angiogenesis inhibitor TNP-470 on human ovarian cancer transplanted subcutaniously in nude mice].
Kong H; Jin Z; Yao M
Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):556-8. PubMed ID: 12411020
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea derivatives of irofulven with improved antitumor efficacy.
Staake MD; Kashinatham A; McMorris TC; Estes LA; Kelner MJ
Bioorg Med Chem Lett; 2016 Apr; 26(7):1836-8. PubMed ID: 26922141
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
Hilgers W; Faivre S; Chieze S; Alexandre J; Lokiec F; Goldwasser F; Raymond E; Kahatt C; Taamma A; Weems G; MacDonald JR; Misset JL; Cvitkovic E
Invest New Drugs; 2006 Jul; 24(4):311-9. PubMed ID: 16683074
[TBL] [Abstract][Full Text] [Related]
20. Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven.
Wang Y; Wiltshire T; Senft J; Wenger SL; Reed E; Wang W
Mol Cancer Ther; 2006 Dec; 5(12):3153-61. PubMed ID: 17172419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
